Early Skin Toxicity Emerges as a Survival Marker in First-Line EVP
Treatment-emergent skin toxic effects may be more than an inconvenience in patients receiving enfortumab vedotin-pembrolizumab for advanced urothelial carcinoma. In a retrospective cohort from the University of Texas MD Anderson Cancer Center, rash or pruritus appearing early during therapy was associated with longer overall survival, raising the possibility that cutaneous toxicity could serve as an early clinical marker of treatment benefit.
The signal was not subtle. Among 185 adults treated with first-line EVP between March 3, 2022, and July 31, 2025, skin toxic effects developed in 98 patients, or 53.0%, at a median of 14 days after treatment start. Those events were usually early, often within the first month, which is exactly when clinicians are trying to decide whether a patient is tolerating therapy well enough to stay on track.
Survival Differences Were Seen Despite Early Dose Changes
The cohort was older, with a median age of 73 years, and predominantly male, reflecting the typical population affected by advanced urothelial carcinoma. Skin toxic effects were not benign in operational terms: they led to EV dose reduction in 31 patients, treatment interruption in 20, and treatment discontinuation in 9. Grade 3 or higher skin toxic effects occurred in 10 patients, or 5.4%, so the toxicity spectrum ranged from common mild symptoms to events serious enough to alter treatment delivery.
Still, the survival pattern favored the group that developed skin toxicity. At a median follow-up of 17.7 months, Simon-Makuch curves showed longer overall survival and progression-free survival among all patients with skin toxic effects compared with those without them. In the subgroup with visceral metastases, overall survival was also longer in the skin-toxicity stratum. The most direct estimate came from the time-dependent Cox model, where skin toxic effects were associated with longer overall survival with a hazard ratio of 0.34 and a 95% CI of 0.20 to 0.57.
That is a substantial association. It suggests that, in this cohort, patients who developed early rash or pruritus were less likely to die during follow-up than those who did not, even after accounting for the timing of toxicity to reduce immortal-time bias.
Why the Analysis Method Matters at the Bedside
This question is easy to distort if timing is ignored. Patients must survive long enough to develop a toxicity, and a simple comparison of those with and without rash can exaggerate any apparent benefit. To avoid that problem, skin toxic effects were handled as a time-dependent exposure in Cox proportional hazards regression, and the investigators also ran sequential adjustment models plus prespecified 30-day landmark analyses.
The association between skin toxic effects and overall survival held across those approaches. Even after additional adjustment, the signal remained consistent, which strengthens confidence that the pattern was not driven entirely by model choice or early treatment timing. The landmark analyses were especially useful because they restricted attention to patients who had already been observed for the first 30 days, when most cutaneous toxicity appears.
In those landmark analyses, the associations with progression-free survival and objective response rate stayed directionally favorable, but the estimates weakened after multivariable adjustment. That is an important boundary. Overall survival carried the clearest association; the response-related endpoints were less robust once other factors were considered.
What the Skin Signal May Be Reflecting
No biological mechanism was directly tested in this study, but the clinical pattern invites a plausible explanation. Enfortumab vedotin targets nectin-4, and pembrolizumab activates antitumor immunity through PD-1 blockade. Skin toxicity could reflect greater drug exposure, stronger immune activation, or a host-tumor interaction that makes both cutaneous adverse effects and antitumor activity more likely to appear in the same patient. The data do not prove any one of those mechanisms, but they make the question worth pursuing.
The practical implication is modest but real: early rash or pruritus during EVP should not automatically be interpreted as a reason to abandon therapy. In this cohort, many patients continued treatment with dose reduction or interruption rather than permanent discontinuation, and the overall survival association remained favorable despite those modifications.
A Narrower Clinical Message for Urothelial Cancer Care
For oncologists managing advanced urothelial carcinoma, the study suggests that treatment-emergent skin toxic effects may identify patients deriving more durable benefit from first-line EVP. It does not mean skin toxicity should be encouraged, nor does it justify ignoring significant rash. Severe events still required treatment changes, and 5.4% of patients experienced grade 3 or higher toxicity.
What it does offer is a clinically recognizable early signal. A patient who develops rash or pruritus soon after starting EVP may belong to a group with better survival, at least in this single-center retrospective experience. That observation could influence how clinicians counsel patients during the first few weeks of therapy and how they think about toxicity management when balancing dose modification against treatment continuity.
Prospective validation remains necessary because retrospective associations can travel only so far. The study was conducted at a single institution, and the number of severe skin events was small. Response analyses were less definitive after adjustment. Even so, the survival signal was strong enough to justify a closer look at skin toxicity as a potential early biomarker of benefit in first-line EVP, especially if future studies can connect the clinical pattern to drug exposure, immune activation, or another underlying mechanism.